Cencora Reaffirms Guidance After Limited Walgreens Volume Shift
Cencora reaffirms $17.75–$17.95 FY2026 EPS after minor Walgreens volume shift. Analysts see just 3–3.5% impact as core prime vendor deal stays intact.
/ 492 items
#XY Event-Driven Stocks↓
Definium’s Experimental LSD Drug Delivers Strong Phase 3 Results in Anxiety Trial
Definium’s one-dose anxiety drug cut symptoms for 12 weeks, with mostly mild side effects, offering hope for a new treatment.
MGNX Rises After Gilead Exercises Option on Bispecific Program
Gilead pays MacroGenics $10 million to license a TRIDENT-based bispecific for solid tumors, extending its cash runway to 2028.
Mereo BioPharma Secures Major Option Deal for Alvelestat and Extends Cash Runway
Mereo BioPharma shares rose ~27% after a key option-and-license deal for alvelestat with Sentynl and an updated cash runway into late 2027.
AC Immune’s ACI-7104 Gets FDA Fast Track Designation for Early Parkinson’s Disease
AC Immune’s ACI-7104 receives FDA Fast Track and IND clearance for early Parkinson’s. Phase 2 VacSYn trial can now expand to US sites.
Sell-the-News Hits MoonLake: Strong Sonelokimab Data Fail to Impress vs. Bimzelx
Strong results matched but did not beat Bimzelx, triggering sell-the-news.